Clinical trials: SARS-CoV-2
Health Behavior, Health Care Utilization
COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos)
The global SARS-CoV-2 pandemic that causes the severe respiratory illness COVID-19 is the worst health crisis that the United States has faced in a century.
- Trial name
- OSJP (NCT04793464)
- Testing
- Promotores de Salud, Services as usual
- Where
- United States
- Volunteers
- 1,623 people
- Sponsor
- University of Oregon
Covid19
The Impact of Vaccination on Severity of Illness in COVID-19
With the FDA's emergency use authorization declaration in December of 2020, the Pfizer-BioNtech vaccine became the first of several vaccines to kick off the mass vaccination effort across the United States against CoronaVIrus…
- Trial name
- NCT04912700
- Testing
- COVID-19 vaccine
- Where
- United States
- Volunteers
- 11,834 people
- Sponsor
- Corewell Health East
Kidney Transplant Recipients
COVID-19 Protection After Transplant Pilot Study
Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who…
- Trial name
- CPAT (NCT04969263)
- Testing
- BNT162b2 vaccine (Pfizer/BioNTech), mRNA-1273 vaccine (Moderna)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Sars-CoV2
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe…
- Conditions
- COVID-19, Sars-CoV2, Pneumonia
- Trial name
- NCT04463004
- Testing
- Mavrilimumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Virginia Commonwealth University
Covid-19 Prevention
A Study of Ad26.COV2.S in Adults (COVID-19)
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination…
- Trial name
- NCT04436276
- Testing
- Ad26.COV2.S
- Where
- 12 sites in United States, Belgium
- Volunteers
- 1,085 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Covid19
Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
This is a 2-part, 2-arm, Phase 2 , multicentre, randomized, double-blind, placebo-controlled study in adults with COVID-19 with gastrointestinal infection.
- Trial name
- RESERVOIR (NCT04858425)
- Testing
- Niclosamide
- Where
- 25 sites in United States, India and 1 more
- Volunteers
- 166 people
- Sponsor
- Entero Therapeutics
Covid19
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
This study proposes to evaluate the therapeutic efficacy, immunologic effects and normalization of laboratory parameters for patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19) when administered one unit…
- Trial name
- NCT04513158
- Testing
- Convalescent Plasma
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Joseph M. Flynn, D.O., MPH
Severe Acute Respiratory Syndrome, Coronavirus
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.
- Conditions
- Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2, COVID-19
- Trial name
- NCT04449276
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- CureVac
COVID-19, Long COVID
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e.
- Trial name
- MEADOWSPRING (NCT05059080)
- Where
- 35 sites in Argentina, Belgium and 8 more
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
Invasive Fungal Infections
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
- Trial name
- AEGIS (NCT04240886)
- Testing
- fosmanogepix
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
COVID-19, SARS-CoV-2
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
- Trial name
- NCT04516746
- Testing
- AZD1222
- Where
- 84 sites in United States, Chile and 1 more
- Volunteers
- 32,450 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Health Behavior, Health Care Utilization
RADx-UP Phase 3D (Oregon Saludable: Juntos Podemos)
The ongoing Oregon Saludable: Juntos Podemos (OSJP, Healthy Oregon: Together We Can) project was developed to directly address the COVID-19 related health disparities among Latinx communities through community engagement funded…
- Conditions
- Health Behavior, Health Care Utilization, Vaccine Hesitancy
- Trial name
- NCT05910879
- Testing
- Self-Affirmation Implementation Intentions (SAII) Intervention, Promotores de Salud (Health Education)
- Where
- United States
- Volunteers
- 625 people
- Sponsor
- University of Oregon
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID
Convalescent Plasma in the Treatment of COVID 19
The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID, Coronavirus
- Trial name
- NCT04343261
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Trinity Health Of New England
COVID-19
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
Low doses of radiation in the form of chest X-rays have been used to treat people with pneumonia. This treatment was found to be effective by reducing inflammation and with minimal side effects.
- Trial name
- VENTED (NCT04427566)
- Testing
- Radiation therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ohio State University
COVID-19 Severe Pneumonia, Acute Lung Injury
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute…
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- NCT04369469
- Testing
- Ravulizumab, BSC
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 202 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Postacute Sequelae of Sars-CoV-2, Post-Acute COVID-19 Syndrome
Transcutaneous Electrical Nerve Stimulation (TENS) in Patients With Postacute Sequelae of Sars-CoV-2
The purpose of the pilot study is to examine acceptability and proof of concept effectiveness of a wireless TENS technology to address PASC associated FM.
- Conditions
- Postacute Sequelae of Sars-CoV-2, Post-Acute COVID-19 Syndrome, Widespread Chronic Pain, Fatigue Syndrome, Chronic
- Trial name
- NCT05200858
- Testing
- TENS - high-dose, TENS - low-dose
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baylor College of Medicine
COVID-19
Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19
The HCW Prophylaxis (HCWP) Study, single, open and off label intervention study. Up to 350 participants will be assigned to group that takes HCQ or group that opts to not take study medication.
- Trial name
- NCT04435808
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID
Paxlovid for Treatment of Long Covid
The purpose of this study is to compare whether being treated with nirmatrelvir plus ritonavir for 15 days works better than being treated with placebo plus ritonavir to reduce severe symptoms of Long Covid.
- Trial name
- STOP-PASC (NCT05576662)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Stanford University
SARS-CoV Infection, Covid19
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
This is a randomized, observer-blinded, Phase 1/2 study evaluating the safety and immunogenicity of a quadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle combination vaccine with Matrix-M1 adjuvant; this…
- Trial name
- NCT04961541
- Testing
- ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant
- Where
- 10 sites in Australia
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- Novavax
Covid19, SARS-CoV2 Infection
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19 vaccines in: People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study.
- Trial name
- NCT04952402
- Testing
- Study-provided Moderna mRNA-1273 COVID-19 vaccine, Community-provided Moderna mRNA-1273 COVID-19 Vaccine, Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
- Where
- 6 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)